Enoxaparin

• DVT Prevention and Treatment
• Pulmonary Embolism
• Acute Coronary Syndromes
• Anticoagulation Therapy

Enoxaparin is a low molecular weight heparin (LMWH) anticoagulant used for the prevention and treatment of venous thromboembolism and in acute coronary syndromes. This injectable anticoagulant offers predictable pharmacokinetics, subcutaneous dosing, and reduced monitoring requirements compared to unfractionated heparin.

Mechanism of Action

Enoxaparin is produced by controlled depolymerization of unfractionated heparin, resulting in fragments with a mean molecular weight of about 4,500 daltons. Like heparin, enoxaparin enhances the activity of antithrombin III (AT), but with a more selective mechanism. Enoxaparin has a higher ratio of anti-factor Xa to anti-factor IIa (thrombin) activity (approximately 4:1) compared to unfractionated heparin (1:1). This preferential inhibition of factor Xa prevents thrombin generation while causing less effect on thrombin directly, potentially reducing bleeding risk while maintaining efficacy. The predictable dose-response and longer half-life allow weight-based dosing without routine laboratory monitoring.

Available Formulations

Enoxaparin sodium is available as a solution for subcutaneous or intravenous injection in prefilled syringes and multi-dose vials. Concentrations include 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL, 120 mg/0.8 mL, and 150 mg/1 mL. Multi-dose vials (300 mg/3 mL) contain benzyl alcohol as a preservative and should not be used in neonates or pregnant women.

Medical Uses

Enoxaparin is FDA-approved for prophylaxis of DVT in hip replacement, knee replacement, and abdominal surgery; prophylaxis of DVT in medical patients with severely restricted mobility; inpatient treatment of acute DVT with or without PE; outpatient treatment of acute DVT without PE; prophylaxis of ischemic complications of unstable angina and non-Q-wave MI; and treatment of acute STEMI. It is one of the most widely used anticoagulants in hospital and outpatient settings.

Dosing Guidelines

For DVT prophylaxis, doses range from 30 mg SC every 12 hours to 40 mg SC once daily depending on surgical procedure and patient risk. For DVT/PE treatment, the dose is 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily. For acute coronary syndromes, 1 mg/kg SC every 12 hours with concurrent aspirin is used. For STEMI, an initial IV bolus is followed by SC dosing. Dose adjustment is required for CrCl less than 30 mL/min (typically once daily dosing instead of twice daily). Anti-Xa monitoring may be helpful in certain populations.

Important Safety Information

Enoxaparin carries a boxed warning for spinal/epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture, which may result in long-term or permanent paralysis. Risk factors include indwelling epidural catheters, concurrent use of other drugs affecting hemostasis, traumatic or repeated spinal puncture, and spinal deformity or surgery. Hemorrhage is the primary adverse effect. The medication should be used with caution in patients with renal impairment, low body weight, or conditions predisposing to bleeding.

Drug Interactions

Drugs affecting hemostasis (anticoagulants, antiplatelet agents, NSAIDs, thrombolytics) increase bleeding risk. Concurrent use with other LMWHs, heparin, or heparinoids should be avoided. Probenecid may increase enoxaparin levels. No significant interactions with digoxin, warfarin (at steady state), or common medications when used appropriately.

Choosing Between Enoxaparin and an Oral Anticoagulant

Enoxaparin and the direct oral anticoagulants treat the same clots, and the decision between them is usually made on circumstances rather than on potency. Enoxaparin remains the preferred agent in pregnancy, because it does not cross the placenta and the oral agents have not been established as safe there. It is preferred in active cancer, where injectable low molecular weight heparin has the longest record and where absorption is not disrupted by vomiting or by bowel surgery. It is preferred in any patient who cannot reliably absorb or keep down a tablet. And it is used as a bridge in the first days of treatment for deep venous thrombophlebitis or pulmonary embolism when warfarin is the long-term plan, since warfarin takes several days to become therapeutic and is transiently procoagulant at the start. It is also the drug chosen around many surgical procedures, where a short half-life is worth more than the convenience of a tablet.

Against it are the injections themselves and the cost of syringes over months. For a patient with an uncomplicated first clot and normal kidney function, an oral agent such as apixaban or rivaroxaban is often started instead and no injection is needed at all. Kidney function drives the choice in the other direction as well: enoxaparin is cleared renally, accumulates when clearance falls, and requires the dose adjustment described above, so advanced kidney disease sometimes favors unfractionated heparin in the hospital instead. A history of heparin-induced thrombocytopenia rules enoxaparin out entirely, and fondaparinux is one of the alternatives used in that setting.

Injection Technique, Platelet Counts and the Bruise That Is Normal

Most of the difficulty patients have with enoxaparin is mechanical rather than pharmacological. The prefilled syringe contains an air bubble that should not be expelled; it is there to clear the needle and deliver the full dose into the tissue. Injections go into the fat of the abdomen, several inches away from the navel, alternating sides each time, with the skin fold held until the needle is withdrawn. Rubbing the site afterward enlarges the bruise. Bruising at the injection site is expected and is not a reason to stop. What is not expected is bleeding that will not stop, black or tarry stools, red or brown urine, coughing up blood, an unusually severe headache, or new leg weakness, numbness, or back pain in someone who has recently had spinal or epidural anesthesia, which may signal the hematoma described in the boxed warning.

A platelet count before starting and again during the first two weeks is standard practice, because heparin-induced thrombocytopenia typically declares itself between about the fifth and tenth day and is recognized by a falling count rather than by any symptom. Missed doses are the other common failure. This drug loses its effect within a day, so a two-day gap while a prescription is refilled or a prior authorization is processed leaves a patient unprotected in a way that a missed warfarin dose does not. Patients who are traveling should carry syringes in a carry-on bag with the pharmacy label attached. The MedlinePlus enoxaparin monograph walks through the injection steps in patient language, and the NHLBI overview of venous thromboembolism explains why anticoagulation continues for months after the clot itself has resolved. Practical advice for patients who have had a clot and travel long distances is in our article on blood clots and snowbird travel, and our hematology team handles the anticoagulation questions that come up between visits.

Special Populations

Enoxaparin has been used during pregnancy; the multi-dose vials should not be used due to benzyl alcohol content. It is the preferred anticoagulant in many pregnancy situations but requires careful monitoring. Small amounts may be present in breast milk; caution is advised. The multi-dose vial should not be used in neonates due to benzyl alcohol toxicity risk. Elderly patients may have reduced enoxaparin clearance. Dose adjustment is required for severe renal impairment (CrCl less than 30 mL/min). Use with caution in hepatic impairment; patients with hepatic dysfunction may have reduced AT levels.